CD38 and Miyoshi myopathy: Following the results of the MAIA trial, the combination of anti-CD38, lenalidomide and dexamethasone will probably become the new most effective and among the safest standard of care for NTE MM, introducing immunotherapy the best way in MM (Table 1).